The impact of GLP-1R agonists such as semaglutide extends beyond diabetes control: they play a multifaceted role in regulating blood glucose levels by reducing hunger, moderating food intake, and managing body weight [36]
Moreover, the SURMOUNTMMO (tirzepatide, NCT05556512) will assess the impact of the dual GLP-1/GIP RA in cardiovascular outcomes and all-cause mortality for people with obesity (without diabetes) when the REDEFINE-3 study will assess the impact of cagrisema in people with obesity (with and without T2DM) and established cardiovascular disease
This article is not medical advice
GLP-1 medications are still relatively new, so not all long-term side effects are known, but they are found to be generally safe for those prescribed
10.2337/db08-0958
[29] Those two novel peptides were later isolated, identified, and investigated by other researchers, and are now known as glucagon-like peptide-1 and glucagon-like peptide-2